Evolution of surgical treatment of metastatic spine tumors.
Cancer
Metastasis
NOMS
Spine
Tumor
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
31
12
2021
accepted:
04
03
2022
pubmed:
21
3
2022
medline:
23
4
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
The treatment of cancer has transformed over the past 40 years, with medical oncologists, radiation oncologists and surgeons working together to prolong survival times and minimize treatment related morbidity. With each advancement, the risk-benefit scale has been calibrated to provide an accurate assessment of surgical hazard. The goal of this review is to look back at how the role of surgery has evolved with each new medical advance, and to explore the role of surgeons in the future of cancer care. A literature review was conducted, highlighting the key papers guiding surgical management of spinal metastatic lesions. The roles of surgery, medical therapy, and radiation have evolved over the past 40 years, with new advances requiring complex multidisciplinary care.
Identifiants
pubmed: 35306618
doi: 10.1007/s11060-022-03982-0
pii: 10.1007/s11060-022-03982-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-283Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Perrin RG (1989) Symptomatic spinal metastases. Am Fam Phys 39:165–172
Todd B (1990) Management of painful unstable spinal metastases. Br J Hosp Med 43:328
Shaw B, Mansfield FL, Borges L (1989) One-stage posterolateral decompression and stabilization for primary and metastatic vertebral tumors in the thoracic and lumbar spine. J Neurosurg 70:405–410
doi: 10.3171/jns.1989.70.3.0405
O’Neil J, Gardner V, Armstrong G (1988) Treatment of tumors of the thoracic and lumbar spinal column. Clin Orthop Relat Res 227:103–112
Kashab M, Böker DK (1988) Indication for surgery of spinal metastases within the cervical region. Neurosurg Rev 11:95–97
doi: 10.1007/BF01795700
Onimus M, Schraub S, Bertin D, Bosset JF, Guidet M (1986) Surgical treatment of vertebral metastasis. Spine 11:883–891
doi: 10.1097/00007632-198611000-00007
Sundaresan N, Digiacinto GV, Hughes JE (1986) Surgical treatment of spinal metastases. Clin Neurosurg 33:503–522
Sundaresan N, Galicich JH, Bains MS, Martini N, Beattie EJJ (1984) Vertebral body resection in the treatment of cancer involving the spine. Cancer 53:1393–1396
doi: 10.1002/1097-0142(19840315)53:6<1393::AID-CNCR2820530629>3.0.CO;2-0
Barcena A et al (1984) Spinal metastatic disease: analysis of factors determining functional prognosis and the choice of treatment. Neurosurgery 15:820–827
Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113
doi: 10.1097/00007632-199011010-00005
Patchell RA et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648
doi: 10.1016/S0140-6736(05)66954-1
Fourney DR et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:3072–3077
doi: 10.1200/JCO.2010.34.3897
Chen C, Lee I, Tatsui C, Elder T, Sloan AE (2021) Laser interstitial thermotherapy (LITT) for the treatment of tumors of the brain and spine: a brief review. J Neurooncol 151:429–442
doi: 10.1007/s11060-020-03652-z
Vega RA, Ghia AJ, Tatsui CE (2020) Percutaneous hybrid therapy for spinal metastatic disease: laser interstitial thermal therapy and spinal stereotactic radiosurgery. Neurosurg Clin N Am 31:211–219
doi: 10.1016/j.nec.2019.11.006
Hadzipasic M, Giantini-Larsen AM, Tatsui CE, Shin JH (2020) Emerging percutaneous ablative and radiosurgical techniques for treatment of spinal metastases. Neurosurg Clin N Am 31:141–150
doi: 10.1016/j.nec.2019.08.017
Thomas JG et al (2017) A novel use of the intraoperative MRI for metastatic spine tumors: laser interstitial thermal therapy for percutaneous treatment of epidural metastatic spine disease. Neurosurg Clin N Am 28:513–524
doi: 10.1016/j.nec.2017.05.006
Zhang C et al (2020) Posterior decompression surgery and radiofrequency ablation followed by vertebroplasty in spinal metastases from lung cancer. Med Sci Monit 26:e925169
Caruso JP, Cohen-Inbar O, Bilsky MH, Gerszten PC, Sheehan JP (2015) Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. Neurosurg Focus 38:E6
doi: 10.3171/2014.11.FOCUS14716
Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM (2005) Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg 83:213–221
doi: 10.1159/000091952
Katsoulakis E, Kumar K, Laufer I, Yamada Y (2017) Stereotactic body radiotherapy in the treatment of spinal metastases. Semin Radiat Oncol 27:209–217
doi: 10.1016/j.semradonc.2017.03.004
Barzilai O et al (2018) Predictors of quality of life improvement after surgery for metastatic tumors of the spine: prospective cohort study. Spine J 18:1109–1115
doi: 10.1016/j.spinee.2017.10.070
Laufer I et al (2013) Local disease control for spinal metastases following ‘separation surgery’ and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18:207–214
doi: 10.3171/2012.11.SPINE12111
Lockney DT et al (2017) Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment. Neurosurg Focus 42:E4
doi: 10.3171/2016.9.FOCUS16373
Redmond KJ et al (2017) Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey. J Neurosurg Spine 26:299–306
doi: 10.3171/2016.8.SPINE16121
Gerszten PC, Mendel E, Yamada Y (2009) Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 34:S78-92
doi: 10.1097/BRS.0b013e3181b8b6f5
Moussazadeh N, Laufer I, Yamada Y, Bilsky MH (2014) Separation surgery for spinal metastases: effect of spinal radiosurgery on surgical treatment goals. Cancer Control 21:168–174
doi: 10.1177/107327481402100210
Barzilai O et al (2019) Hybrid therapy for metastatic epidural spinal cord compression: technique for separation surgery and spine radiosurgery. Oper Neurosurg 16:310–318
doi: 10.1093/ons/opy137
Bilsky M, Smith M (2006) Surgical approach to epidural spinal cord compression. Hematol Oncol Clin N Am 20:1307–1317
doi: 10.1016/j.hoc.2006.09.009
Sahgal A et al (2013) Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 85:341–347
doi: 10.1016/j.ijrobp.2012.05.007
Itshayek E et al (2010) Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review. Int J Oncol 36:533–544
Harel R et al (2010) Spine instrumentation failure after spine tumor resection and radiation: comparing conventional radiotherapy with stereotactic radiosurgery outcomes. World Neurosurg 74:517–522
doi: 10.1016/j.wneu.2010.06.037
Ling DC et al (2018) Long-term outcomes after stereotactic radiosurgery for spine metastases: radiation dose-response for late toxicity. Int J Radiat Oncol Biol Phys 101:602–609
doi: 10.1016/j.ijrobp.2018.02.035
Jawad MS et al (2016) Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation. J Neurosurg Spine 24:928–936
doi: 10.3171/2015.10.SPINE141261
Roesch J et al (2017) Risk for surgical complications after previous stereotactic body radiotherapy of the spine. Radiat Oncol 12:153
doi: 10.1186/s13014-017-0887-8
Qian Z et al (2011) Kyphoplasty for the treatment of malignant vertebral compression fractures caused by metastases. J Clin Neurosci 18:763–767
doi: 10.1016/j.jocn.2010.09.021
Konig MA et al (2012) Kyphoplasty for lytic tumour lesions of the spine: prospective follow-up of 11 cases from procedure to death. Eur Spine J 21:1873–1879
doi: 10.1007/s00586-012-2264-5
Eleraky M et al (2011) Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine. J Neurosurg Spine 14:372–376
doi: 10.3171/2010.11.SPINE09909
Laufer I et al (2013) The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 18:744–751
doi: 10.1634/theoncologist.2012-0293
Nasrallah H, Yamada Y, Laufer I, Bilsky MH (2019) A NOMS framework solution. Int J Radiat Oncol Biol Phys 103:17–18
doi: 10.1016/j.ijrobp.2018.09.026
Bollen L et al (2016) Predictive value of six prognostic scoring systems for Spinal bone metastases: an analysis based on 1379 patients. Spine 41:E155-162
doi: 10.1097/BRS.0000000000001192
Cassidy JT, Baker JF, Lenehan B (2018) The role of prognostic scoring systems in assessing surgical candidacy for patients with vertebral metastasis: a narrative review. Global Spine J 8:638–651
doi: 10.1177/2192568217750125
Choi D et al (2018) Prediction accuracy of common prognostic scoring systems for metastatic spine disease: results of a prospective international multicentre study of 1469 patients. Spine 43:1678–1684
doi: 10.1097/BRS.0000000000002576
Cui Y, Lei M, Pan Y, Lin Y, Shi X (2020) Scoring algorithms for predicting survival prognosis in patients with metastatic spinal disease: the current status and future directions. Clin Spine Surg 33:296–306
doi: 10.1097/BSD.0000000000001031
Douglas S, Schild SE, Rades D (2012) A new score predicting the survival of patients with spinal cord compression from myeloma. BMC Cancer 12:425
doi: 10.1186/1471-2407-12-425
Rades D et al (2012) Prognostic factors in a series of 504 breast cancer patients with metastatic spinal cord compression. Strahlenther Onkol 188:340–345
doi: 10.1007/s00066-011-0061-4
Tokuhashi Y, Uei H, Oshima M, Ajiro Y (2014) Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop 5:262–271
doi: 10.5312/wjo.v5.i3.262
Lehmann BD et al (2020) TBCRC 032 IB/II Multicenter Study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin Cancer Res 26:2111–2123
doi: 10.1158/1078-0432.CCR-19-2170
Li Q et al (2019) Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase I clinical trial. Clin Cancer Res 25:5212–5220
doi: 10.1158/1078-0432.CCR-18-4173
Alva AS et al (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 39:2443–2451
doi: 10.1200/JCO.20.02923
Criscitiello C et al (2021) Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. Eur J Cancer 157:40–49
doi: 10.1016/j.ejca.2021.07.037
Hui R et al (2020) Lucitanib for the treatment of HR(+)/HER2(-) metastatic breast cancer: results from the multicohort phase II FINESSE study. Clin Cancer Res 26:354–363
doi: 10.1158/1078-0432.CCR-19-1164
Kim J-Y et al (2019) Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. Int J Cancer 145:1669–1678
doi: 10.1002/ijc.32188
Tung NM et al (2020) TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38:4274–4282
doi: 10.1200/JCO.20.02151
Xing Y et al (2019) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21:78
doi: 10.1186/s13058-019-1154-8
Lin H-H et al (2020) Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups. Spinal Cord 58:194–202
doi: 10.1038/s41393-019-0352-7
Zhao J et al (2016) Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized studies. PLoS ONE 11:e0157455
doi: 10.1371/journal.pone.0157455
Zhu Y, Zhu X, Tang C, Guan X, Zhang W (2021) Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer 1876:188593
doi: 10.1016/j.bbcan.2021.188593
Gokaslan ZL, Aladag MA, Ellerhorst JA (2000) Melanoma metastatic to the spine: a review of 133 cases. Melanoma Res 10:78–80
doi: 10.1097/00008390-200010010-00010
Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
doi: 10.1056/NEJMoa1200694
Seung SK et al (2012) Phase 1 study of stereotactic body radiotherapy and interleukin-2–tumor and immunological responses. Sci Transl Med 4:137–174
doi: 10.1126/scitranslmed.3003649
Prieto PA et al (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039–2047
doi: 10.1158/1078-0432.CCR-11-1823
Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
doi: 10.1056/NEJMoa1200690
Weber JS et al (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530–534
doi: 10.1097/CMR.0b013e32834d3d88
Hamid O et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
doi: 10.1056/NEJMoa1305133
Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
doi: 10.1056/NEJMoa1103782
Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819
doi: 10.1056/NEJMoa1002011
Postow MA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931
doi: 10.1056/NEJMoa1112824
Zairi F et al (2016) Evaluation of the relevance of surgery in a retrospective case series of patients who underwent the surgical treatment of a symptomatic spine metastasis from lung cancer. Eur Spine J 25:4052–4059
doi: 10.1007/s00586-016-4397-4
Truong VT et al (2021) Surgical intervention for patients with spinal metastasis from lung cancer: a retrospective study of 87 cases. Clin Spine Surg 34:E133–E140
doi: 10.1097/BSD.0000000000001062
Amelot A et al (2020) Spinal metastases from lung cancer: survival depends only on genotype, neurological and personal status, scarcely of surgical resection. Surg Oncol 34:51–56
doi: 10.1016/j.suronc.2020.03.005
Kumar N et al (2018) The influence of histologic subtype in predicting survival of lung cancer patients with spinal metastases. Clin Spine Surg 31:E1–E7
doi: 10.1097/BSD.0000000000000475
Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092
doi: 10.1056/NEJMoa1801005
Ishihara H et al (2021) Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. Jpn J Clin Oncol 51:793–801
doi: 10.1093/jjco/hyaa232
Ishihara H et al (2021) Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Jpn J Clin Oncol 51:296–304
doi: 10.1093/jjco/hyaa171
Oza B et al (2021) RAMPART: a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials 108:106482
doi: 10.1016/j.cct.2021.106482
Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK (2019) The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions. Curr Treat Options Oncol 20:41
doi: 10.1007/s11864-019-0638-1
Goodwin CR et al (2018) The challenges of renal cell carcinoma metastatic to the spine: a systematic review of survival and treatment. Global Spine J 8:517–526
doi: 10.1177/2192568217737777
Alhalabi O et al (2021) Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: the MD Anderson Cancer Center experience. Int J Cancer 149:387–393
doi: 10.1002/ijc.33560
Bando Y et al (2021) Treatment outcomes of molecular targeted therapy following nivolumab in metastatic renal cell carcinoma. Jpn J Clin Oncol 51:1313–1318
doi: 10.1093/jjco/hyab068
Okuno Y, Tanaka R, Mikami K, Takeuchi T (2020) Renal cancer tissue after nivolumab/ipilimumab combination therapy for metastatic renal cell carcinoma. Hinyokika Kiyo 66:13–17
Tomita Y et al (2021) Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Jpn J Clin Oncol 51:966–975
doi: 10.1093/jjco/hyaa266
Aggen DH, Drake CG, Rini BI (2020) Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting. Clin Cancer Res 26:2087–2095
doi: 10.1158/1078-0432.CCR-19-3323
Osawa T et al (2019) Overview of current and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol 49:395–403
doi: 10.1093/jjco/hyz013